Advisor Group Holdings, Inc. Brainstorm Cell Therapeutics Inc. Transaction History

Advisor Group Holdings, Inc.

$39.8 Billion
Q4 2024

A detailed history of Advisor Group Holdings, Inc. transactions in Brainstorm Cell Therapeutics Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 10,519 shares of BCLI stock, worth $19,249. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,519

Previous 10,519 -0.0%

Holding current value

$19,249

Previous $2,000 1050.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.28 - $0.66 $61 - $145	-220 Reduced 2.05%	10,519 $5,000
Q4 2023 Feb 12, 2024	SELL	$0.15 - $0.4 $635 - $1,695	-4,239 Reduced 28.3%	10,739 $2,000
Q3 2023 Nov 13, 2023	BUY	$0.2 - $2.08 $847 - $8,817	4,239 Added 39.47%	14,978 $2,000
Q2 2023 Aug 10, 2023	SELL	$2.0 - $3.2 $400 - $640	-200 Reduced 1.83%	10,739 $22,000
Q1 2023 May 12, 2023	SELL	$1.43 - $3.3 $143 - $330	-100 Reduced 0.91%	10,939 $36,000
Q4 2022 Feb 10, 2023	BUY	$1.37 - $4.42 $274 - $884	200 Added 1.85%	11,039 $18,000
Q1 2022 May 04, 2022	SELL	$2.92 - $4.19 $236 - $339	-81 Reduced 0.74%	10,839 $1.33 Million
Q2 2021 Aug 02, 2021	SELL	$3.01 - $4.01 $39,313 - $52,374	-13,061 Reduced 54.46%	10,920 $42,000
Q1 2021 May 13, 2021	BUY	$3.46 - $7.88 $7,681 - $17,493	2,220 Added 10.2%	23,981 $92,000
Q4 2020 Feb 10, 2021	SELL	$3.99 - $17.73 $137,028 - $608,901	-34,343 Reduced 61.21%	21,761 $99,000
Q3 2020 Nov 12, 2020	BUY	$11.19 - $16.92 $540,521 - $817,303	48,304 Added 619.28%	56,104 $948,000
Q2 2020 Aug 14, 2020	SELL	$4.42 - $12.66 $3,094 - $8,862	-700 Reduced 8.24%	7,800 $87,000
Q1 2020 May 18, 2020	BUY	$4.01 - $8.88 $34,085 - $75,480	8,500 New	8,500 $40,000

Others Institutions Holding BCLI

# of Institutions

Shares Held

549K

Call Options Held

Put Options Held

View Full List

About BRAINSTORM CELL THERAPEUTICS INC.

Ticker BCLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,486,200
Market Cap $66.8M
Description
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...

More about BCLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.

Account

Advisor Group Holdings, Inc. Brainstorm Cell Therapeutics Inc. Transaction History